FGFR3-driven gene regulatory network analysis reveals a protumoral role for p63 in luminal bladder tumors
Journal of Clinical Investigation · 03.08.2026 · 136 (15)
DOI: 10.1172/jci193280 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 03.08.2026. Verfasst von Aura Moreno-Vega und 32 weiteren Autor:innen. Beteiligte Einrichtung: Institut Curie, Centre National de Recherche Scientifique (CNRS), UMR144, Molecular Oncology team, PSL Research University, Sorbonne Université UPMC …. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Receptor, Fibroblast Growth Factor, Type 3, Gene Regulatory Networks, Tumor Suppressor Proteins. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ligne national contre le cancer, UNIVERSIDAD DE BUENOS AIRES-UBACYT 2020, European Regional Development Fund (FEDER) grants from Science and Innovation.
Abstract (Originalsprache)
Fibroblast growth factor receptor 3 ( FGFR3 ) is one of the most frequently altered genes in bladder cancer, primarily through activating mutations that drive oncogenesis and are enriched in luminal tumors. However, the underlying gene regulatory network (GRN) remains poorly characterized. Here, we constructed an FGFR3 -mutated GRN using a bottom-up bioinformatics approach, integrating transcriptomic data from bladder cancer cell lines, FGFR3 -mutated tumors, and FGFR3 perturbation experiments in human and mouse models. Using publicly available CRISPR/Cas9 screening data, we identified transcription factors from this GRN that regulate the viability of FGFR3 -mutated cells, with a focus on p63 ( TP63 ). We showed that FGFR3 activation upregulates p63 in patient-derived xenografts and cell lines, while single-cell RNA sequencing revealed heterogeneous p63 activation associated with basal differentiation. Functional studies, including TP63 knockdown in FGFR3-dependent in vitro and in vivo models and RNA-seq along with p63 ChIP-seq, demonstrated that p63 directly promotes cell proliferation and migration and uncovered a positive feedback loop between FGFR3 and p63. Together, these findings support p63 as a protumorigenic regulator in FGFR3- mutated tumors despite their luminal differentiation and provide a detailed FGFR3-driven GRN, offering insights into FGFR3-induced oncogenic dependency and potential strategies to circumvent resistance to FGFR inhibitors. FGFR3 mutations drive bladder carcinogenesis. This study identifies a FGFR3 network, including p63, revealing oncogenic dependencies and offering insights into tumor biology and therapies
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut Curie, Centre National de Recherche Scientifique (CNRS), UMR144, Molecular Oncology team, PSL Research University, Sorbonne Université UPMC Université Paris 6, Paris, France.
- Universidad de Buenos Aires, Facultad de Medicina, Instituto de Oncología Ángel H. Roffo, Área de Investigación, Buenos Aires, Argentina.
- Université de Paris-Saclay, Université d'Evry, Genopole, Evry, France.
- Health Science Center, Hubei Minzu University, Enshi, China.
- Univ. Lille, CNRS, INSERM, CHU Lille, UMR9020 - UMR-1277 - Canther, F-59000 Lille, France.
- Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Förderung
- Ligne national contre le cancer
- UNIVERSIDAD DE BUENOS AIRES-UBACYT 2020
- European Regional Development Fund (FEDER) grants from Science and Innovation
- Instituto de Salud Carlos III
- National Natural Science Foundation of China
- Natural Science Foundation of Hubei Province of China
Zitieren
APA
Moreno-Vega, A., Zambrano, M., Estrada-Virrueta, L., Meng, X., Puig, J., Neyret-Kahn, H., Shi, M., Dufour, F., Gilbert, G., Li, K., Groeneveld, C., Fontugne, J., Pérez-Escavy, M., Dhifli, W., Hua, C., Cabel, L., Krucker, C., Tanguy, L., Lindskrog, S. V., …, & Bernard-Pierrot, I. (2026). FGFR3-driven gene regulatory network analysis reveals a protumoral role for p63 in luminal bladder tumors. Journal of Clinical Investigation, 136(15). https://doi.org/10.1172/jci193280
Vancouver
Moreno-Vega A, Zambrano M, Estrada-Virrueta L, Meng X, Puig J, Neyret-Kahn H, et al. FGFR3-driven gene regulatory network analysis reveals a protumoral role for p63 in luminal bladder tumors. Journal of Clinical Investigation. 2026;136(15). doi:10.1172/jci193280
BibTeX
@article{MorenoVega2026,
author = {Moreno-Vega, Aura and Zambrano, Macarena and Estrada-Virrueta, Lilia and Meng, Xiangyu and Puig, Julia and Neyret-Kahn, Helene and Shi, Mingjun and Dufour, Florent and Gilbert, Guerric and Li, Ke and Groeneveld, Clarice and Fontugne, Jacqueline and Pérez-Escavy, Mercedes and Dhifli, Wajdi and Hua, Clément and Cabel, Luc and Krucker, Clémentine and Tanguy, Laura and Lindskrog, Sia Viborg and Beraud, Claire and Langle, Yanina V and Ye, Tao and Tahi, Fariza and Davidson, Irwin and Paramio, Jesus M and Dyrskjøt, Lars and Allory, Yves and Lluel, Philippe and Eiján, Ana Maria and Elati, Mohamed and Radvanyi, François and Lodillinsky, Catalina and Bernard-Pierrot, Isabelle},
title = {FGFR3-driven gene regulatory network analysis reveals a protumoral role for p63 in luminal bladder tumors},
journal = {Journal of Clinical Investigation},
year = {2026},
volume = {136},
number = {15},
doi = {10.1172/jci193280}
}
EUVIMED